CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zelluna ASA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zelluna ASA
Ullernchausseen 64
OSLO, 0379  Norway Ticker: ZLNAZLNA
Business Summary
Zelluna ASA, formerly Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company develops cell therapies for the treatment of cancer patients. Zelluna ASA deals with eliminate solid cancers by unleashing thel elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The Company provides benefit to patients, their families and all those around them, by developing therapies that bring together TCR guidance with the effector functions of allogeneic NK cells (TCR-NK) deploying a mechanism of action that has the potential to be both safe and potent. Zelluna ASA operates worldwide.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board AndersTuv 1/9/2025 1/9/2025
Interim Chief Executive Officer, Chief Financial Officer Hans V.Eid 12/17/2024
Chief Technology Officer AudunTornes
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Zelluna Immunotherapy A.S. Ullernchausseen 64 Oslo Norway
Ultimovacs AB Dag Hammarskjolds Vag 30 Uppsala Sweden

Business Names
Business Name
ULTI
ULTIMO
Ultimovacs AB
Zelluna Immunotherapy A.S.
ZLNA

General Information
Number of Employees: 17 (As of 9/30/2024)
Outstanding Shares: 34,406,061 (As of 12/31/2024)
Shareholders: 41
Stock Exchange: OSL


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 28, 2025